ConMed Makes Play For SurgiQuest To Prop Up Surgery Business
This article was originally published in The Gray Sheet
Executive Summary
ConMed announced a definitive agreement to acquire the privately held SurgiQuest for $265 million, citing the firm's AirSeal laparoscopic access management technology as a key get for its struggling surgery business.
You may also be interested in...
ConMed’s ‘No Smoking’ Drive Has Multiple Benefits In General Surgery
ConMed Corp. is company of two halves ̶ general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.